FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileARS Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SPRY
ARS Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for ARS Pharmaceuticals, Inc. (SPRY) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSPRY
SPRY
ARS Pharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SPRY
  1. Home
  2. Stocks
  3. ARS Pharmaceuticals, Inc.
SP

ARS Pharmaceuticals, Inc.

🇺🇸SPRY•NASDAQ
SP

ARS Pharmaceuticals, Inc.

🇺🇸SPRY•NASDAQ
Market cap
$297.56M

Your view on SPRY

Mkt Cap
$297.56M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About ARS Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Richard E. Lowenthal MSMSEL
Headquarters
3525 Del Mar Heights Road, San Diego, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Richard E. Lowenthal MSMSEL
Headquarters
3525 Del Mar Heights Road, San Diego, CA, US
Description

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray.

The company was incorporated in 2015 and is based in San Diego, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for ARS Pharmaceuticals, Inc.. Starting points for ARS Pharmaceuticals, Inc.: EPS -$2.00, beta 0.88 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for ARS Pharmaceuticals, Inc.. Trailing twelve-month EPS for ARS Pharmaceuticals, Inc. stands at -$2.00. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' target$15.00average of analysts' targets
Current price—

Buy

Targets, low to high

$15.00

Low $15.00

Middle $15.00

High $15.00

Analyst ratings

3 firms, last 12 months
  • Strong Buy0
  • Buy3
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.28−$0.29−$1.81−$0.74
Lowest estimate−$0.34−$0.34−$1.89−$0.87
Highest estimate−$0.21−$0.22−$1.74−$0.64
Number of analysts2233
A year ago−$0.42−$0.61−$1.74—
Growth vs a year ago+32.7%+53.0%−4.0%—

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$29.52M$25.19M$120.44M$165.44M
Lowest estimate$28.12M$24.25M$119.28M$144.34M
Highest estimate$30.92M$26.14M$121.60M$186.54M
Number of analysts3233
A year ago$28.09M$22.68M$84.28M—
Growth vs a year ago+5.1%+11.1%+42.9%—
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for ARS Pharmaceuticals, Inc.. ARS Pharmaceuticals, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold SPRY15 companies · 8 funds
Compare SPRY with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AQSTAquestive Therapeutics, Inc.HealthcareDrug Manufacturers - Specialty & Generic$434.9M
MNKDMannKind CorporationHealthcareBiotechnology$1.2B
XERSXeris Biopharma Holdings, Inc.HealthcareBiotechnology$3.1B
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PZRXQPhaseRx, Inc.HealthcareOTC$1,169
QNCXQuince Therapeutics, Inc.HealthcareNASDAQ$8.8M
QNRXQuoin Pharmaceuticals, Ltd.HealthcareNASDAQ$6.6M
QNTMQuantum BioPharma Ltd.HealthcareNASDAQ$8.3M
QPTFFQuest PharmaTech Inc.HealthcareOTC$2.2M
QTTBQ32 Bio Inc.HealthcareNASDAQ$249.6M
QUREuniQure N.V.HealthcareNASDAQ$1.4B
RAC.AXRace Oncology LimitedHealthcareASX—
RAD.AXRadiopharm Theranostics LimitedHealthcareASX—
RADXRadiopharm Theranostics LimitedHealthcareNASDAQ$812,081
RANIRani Therapeutics Holdings, Inc.HealthcareNASDAQ$33.4M
RAPPRapport Therapeutics, Inc. Common StockHealthcareNASDAQ$1.1B
ETFs holding ARS Pharmaceuticals, Inc.
TickerFundFund assets% of the fund
XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.08%
IWMiShares Russell 2000 ETF$76.6B in assets0.01%
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.00%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.01%
SMLFiShares US Small-Cap Equity Factor ETF$4.2B in assets0.01%
RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.01%
SPGMState Street SPDR Portfolio MSCI Global Stock Market ETF$1.7B in assets0.01%

Largest holders first, then the funds most concentrated in SPRY.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold ARS Pharmaceuticals, Inc., and how their positions are changing. At a $297.6M market value, institutional positions materially move ARS Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by ARS Pharmaceuticals, Inc. executives and directors. Shares of ARS Pharmaceuticals, Inc. have traded between $6.95 and $18.90 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for ARS Pharmaceuticals, Inc.. Coverage tracks ARS Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of ARS Pharmaceuticals, Inc.

SPRY AnalysisWeak
Past
1
Growth
5
Health
1
Profit
1
Value
1